Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹1,299.95
Price@Trade
₹1,299.95
Target Price
₹1,350
Stop Price
₹1,260
Valid Till
Jul 8, 2020 3:20 AM
Margin
₹259,990 approx for 200 Qty
Status
Active
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
AARTIDRUGS
1,255.85
-20.4 (-1.6%)
Updated 03:28 02/07 IST
AARTIDRUGS Buy or Sell - FrontPage Forums
0 Users have submitted 0 trade ideas of Rs. 0 for AARTIDRUGS
Disclaimer0% Bullish
0% Bearish
AARTIDRUGS Buy or Sell - Brokerage Reports
No. of reports in last year
1
No. of analysts
1
Average Consensus Forecast
796
Consensus Potential
-60.33%
AARTIDRUGS Ratings
Long term AARTIDRUGS rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
5/5 (1 Ratings)
Find answers to all your questions on live AARTIDRUGS message board: Is AARTIDRUGS buy or sell? Should I buy AARTIDRUGS shares? Why are AARTIDRUGS shares falling? Should I invest in AARTIDRUGS stock?
- Home
- AARTIDRUGS Forum
AARTIDRUGS Share Price Discussion
N
Reputation: 3,757 • Jun 4 4:41 AM
Share market update: 20 stocks hit 52-week highs on NSE
The BSE Sensex was trading 52.72 points down at 34056.82.
The BSE Sensex was trading 52.72 points down at 34056.82.
The Economic Times
Like
Reply
N
Reputation: 3,757 • Jun 3 8:03 AM
Midcaps may take time to catch-up; 12 names to bet on amid uncertainty
While the large-cap stocks have been rising, experts believe as sectors, mid-caps and small-caps will take a longer time to pick up as bigger companies could be in a better position to grab higher market share in their respective sectors after the lockdown ends.
While the large-cap stocks have been rising, experts believe as sectors, mid-caps and small-caps will take a longer time to pick up as bigger companies could be in a better position to grab higher market share in their respective sectors after the lockdown ends.
Moneycontrol
Like
Reply
G
Reputation: 4,528 • May 27 2:12 AM
#AARTIDRUGS BUY TRIGGERED TARGET 981/1122 SUPPORT SL 770
Like
Reply
N
Reputation: 3,757 • May 21 3:03 AM
Aarti Drugs Consolidated March 2020 Net Sales at Rs 449.64 crore, down 2.07% Y-o-Y
Moneycontrol
Like
Reply
N
Reputation: 3,757 • May 20 9:58 AM
Buy Aarti Drugs; target of Rs 1028: Anand Rathi
Anand Rathi is bullish on Aarti Drugs has recommended buy rating on the stock with a target price of Rs 1028 in its research report dated May 19, 2020.
Anand Rathi is bullish on Aarti Drugs has recommended buy rating on the stock with a target price of Rs 1028 in its research report dated May 19, 2020.
Moneycontrol
Like
Reply
N
Reputation: 3,757 • May 18 7:03 AM
Aarti Drugs Consolidated March 2020 Net Sales at Rs 449.64 crore, down 2.07% Y-o-Y
Moneycontrol
Like
Reply
S
Reputation: 32,634 • May 16 12:39 PM
Aarti Drugs - Q4 FY20 (Audited –Cons)
CMP: 861
Total income from operations at 449.6 Cr
459.1 Cr (-2.11%) YoY | 473.5 Cr (-5.07%) QoQ
Year ending revenue: 1,806 Cr Vs. 1,560 Cr (15.71%)
Net Profit of 58.8 Cr
27.4 Cr (114.61%) YoY 27.7 Cr (114.92%...
Read more...
4
Reply
C
Reputation: 190 • May 15 3:54 AM
Post by ChartArt in AARTIDRUGS community on FrontPage
#ChartArt #EducationalPurposes #AARTIDRUGS #NIFTY50 #NIFTYBANK Good confluence breakout at current level CMP 835 LOOKING BULLISH
#ChartArt #EducationalPurposes #AARTIDRUGS #NIFTY50 #NIFTYBANK Good confluence breakout at current level CMP 835 LOOKING BULLISH
FrontPage
835 to 871 in a single day. 😍😍
Market down but our stock is up.
Like
Reply
E
Reputation: 5,225 • May 15 2:26 AM
#AARTIDRUGS Long Term Range Breakout.
If This Breakout IS Real And Not a False One then We can Expect A Minimum Move till 1000 And Beyond.
(This Chart Is Also Useful For An Investor).
7
Reply
C
Reputation: 190 • May 14 8:47 AM
Good confluence breakout at current level CMP 835 LOOKING BULLISH
Like
Reply
T
Reputation: -540 • Apr 27 5:28 AM
(TMT) AARTI DRUGS LTD. (740.35):- AS PER CHART NEAR TO RESISTANCE ZONE, ENTER AT CMP SUPPORT 720-700, FIRST HURDLE AT 800 AND CROSS AND CLOSE ABOVE THEN POSSIBLE 1000+
Like
Reply
N
Reputation: 3,757 • Feb 24 7:43 AM
Brokerages see Sensex around 43,650 in a year; top investment ideas post Q3
Prabhudas Lilladher also revised its 12-month Nifty target to 13,461 (against 13,306 earlier), saying the Nifty gains would be a function of economic revival and fallout of coronavirus.
Prabhudas Lilladher also revised its 12-month Nifty target to 13,461 (against 13,306 earlier), saying the Nifty gains would be a function of economic revival and fallout of coronavirus.
Moneycontrol
Like
Reply
N
Reputation: 3,757 • Feb 24 7:38 AM
Brokerages see Nifty around 13,350 & Sensex around 43,650 in a year; 10 investment ideas
Prabhudas Lilladher also revised its 12-month Nifty target to 13,461 (against 13,306 earlier), saying the Nifty gains would be a function of economic revival and fallout of coronavirus.
Prabhudas Lilladher also revised its 12-month Nifty target to 13,461 (against 13,306 earlier), saying the Nifty gains would be a function of economic revival and fallout of coronavirus.
Moneycontrol
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
AARTIDRUGS Share Price - Technicals
- NewsBotJun 4 4:41 AMShare market update: 20 stocks hit 52-week highs on NSEThe Economic TimesNewsBotJun 3 8:03 AMMidcaps may take time to catch-up; 12 names to bet on amid uncertaintyMoneycontrolNewsBotMay 21 3:03 AMAarti Drugs Consolidated March 2020 Net Sales at Rs 449.64 crore, down 2.07% Y-o-YMoneycontrolNewsBotMay 20 9:58 AMBuy Aarti Drugs; target of Rs 1028: Anand RathiMoneycontrolNewsBotMay 18 7:03 AMAarti Drugs Consolidated March 2020 Net Sales at Rs 449.64 crore, down 2.07% Y-o-YMoneycontrolNewsBotFeb 24 7:43 AMBrokerages see Sensex around 43,650 in a year; top investment ideas post Q3MoneycontrolNewsBotFeb 24 7:38 AMBrokerages see Nifty around 13,350 & Sensex around 43,650 in a year; 10 investment ideasMoneycontrolNewsBotOct 24, 2019 9:18 AM
Aarti Drugs Consolidated September 2019 Net Sales at Rs 477.50 crore, up 37.45% Y-o-YMoneycontrolNewsBotJul 29, 2019 2:13 AM
Stocks in the news: ICICI Bank, Cadila Health, Mahindra Life, Vedanta, Uflex, Granules, NHPCmoneycontrol.comNewsBotJul 29, 2019 1:18 AM
Stocks in the news: ICICI Bank, Cadila Health, Mahindra Life, Vedanta, Uflex, Granules Indiawww.moneycontrol.com
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.